Aardvark Therapeutics (AARD) Cash from Investing Activities (2024 - 2026)
Aardvark Therapeutics (AARD) reported Cash from Investing Activities of $34.2 million for Q1 2026, up 130.41% on a YoY basis from $14.9 million in Q1 2025, and up 40.93% sequentially from $24.3 million in Q4 2025.
Aardvark Therapeutics (AARD) Cash from Investing Activities (2024 - 2026) Analysis & Trends
Aardvark Therapeutics (AARD) has 3 years of Cash from Investing Activities data on file, last reported at $34.2 million in Q1 2026.
- For the quarter ending Q1 2026, Cash from Investing Activities rose 130.41% year-over-year to $34.2 million; the trailing twelve-month figure through Mar 2026 stood at $97.2 million (up 178.0% YoY), and the FY2025 full-year result was -$49.7 million, down 313.96% from the prior year.
- Cash from Investing Activities advanced to $34.2 million in Q1 2026, from $24.3 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $34.2 million in Q1 2026 to a low of -$112.6 million in Q1 2025.
- A 3-year average of -$3.0 million and a median of -$5000.0 in 2024 frame the typical range for Cash from Investing Activities.
- Peak annual rise in Cash from Investing Activities reached 585020.0% in 2025, while the deepest fall reached 2252380.0% in 2025.
- Tracing AARD's Cash from Investing Activities over 3 years: stood at -$11.9 million in 2024, then jumped by 304.3% to $24.3 million in 2025, then soared by 40.93% to $34.2 million in 2026.
- Business Quant data shows AARD's Cash from Investing Activities at $34.2 million in Q1 2026, $24.3 million in Q4 2025, and $29.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | 172.62 Mn |
| 10 | Aardvark Therapeutics | 144.97 Mn | 25.00 Mn | - | 34.25 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 34.25 Mn |
| Mar 31, 2026 | 34.25 Mn |
| Dec 31, 2025 | 24.30 Mn |
| Dec 31, 2025 | 24.30 Mn |
| Sep 30, 2025 | 29.25 Mn |
| Sep 30, 2025 | 29.25 Mn |
| Jun 30, 2025 | 9.41 Mn |
| Jun 30, 2025 | 9.41 Mn |
| Mar 31, 2025 | -112.62 Mn |
| Mar 31, 2025 | -112.62 Mn |
| Dec 31, 2024 | -11.90 Mn |
| Dec 31, 2024 | -11.90 Mn |
| Sep 30, 2024 | -5,000.00 |
| Sep 30, 2024 | -5,000.00 |
| Jun 30, 2024 | -93,000.00 |
| Jun 30, 2024 | -93,000.00 |
| Mar 31, 2024 | -5,000.00 |
| Mar 31, 2024 | -5,000.00 |